This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, M.
Right arrow Articles by Zavala, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, M.
Right arrow Articles by Zavala, F.

 Previous Article  |  Next Article 

J Virol, August 1998, p. 6907-6910, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Recombinant Sindbis Viruses Expressing a Cytotoxic T-Lymphocyte Epitope of a Malaria Parasite or of Influenza Virus Elicit Protection against the Corresponding Pathogen in Mice

Moriya Tsuji,1 Cornelia C. Bergmann,2 Yoshiko Takita-Sonoda,1 Ken-Ichiro Murata,1 Elaine G. Rodrigues,1 Ruth S. Nussenzweig,1 and Fidel Zavala1,*

Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York 10010,1 and Department of Neurology, University of Southern California, Los Angeles, California 900332

Received 7 January 1998/Accepted 11 May 1998

    ABSTRACT
Top
Abstract
Text
References

Subcutaneous administration in mice of recombinant Sindbis viruses expressing a class I major histocompatibility complex-restricted 9-mer epitope of the Plasmodium yoelii circumsporozoite protein or the nucleoprotein of influenza virus induces a large epitope-specific CD8+ T-cell response. This immunization also elicits a high degree of protection against infection with malaria or influenza A virus.

    TEXT
Top
Abstract
Text
References

Alpha-RNA viruses such as Sindbis, Semliki Forest, and Venezuelan equine encephalitis viruses are attractive vectors for gene therapy and vaccine development because of their capacities to express large amounts of foreign proteins (7, 10, 24). Sindbis virus offers certain additional advantages, such as a broad range of susceptible host cells (23) and the relative ease of engineering and manipulating recombinant (RE) RNA molecules (10). It is also important that, in spite of its small size of approximately 11.8 kb, this virus is capable of expressing foreign inserts of up to 3.2 kb (18).

Earlier data demonstrated the potential of RE Sindbis viruses, expressing foreign antigen, to induce immunity against a variety of intracellular pathogens (10, 14, 18). We have determined the capacity of these RE viruses expressing the corresponding foreign antigen or epitope to generate CD8+ T-cell responses and protection against infection by the malaria parasite Plasmodium yoelii and the influenza A virus, respectively. In both systems, CD8+ T cells were shown to play major roles in mediating protective immunity (2, 8, 13, 19, 22).

RE Sindbis viruses expressing a minigene coding only for the CD8+ T-cell epitope SYVPSAEQI of the circumsporozoite (CS) protein of P. yoelii (SIN.Mal), recognized by H-2d mice, or TYQRTRALV from the nucleoprotein (NP) of the influenza A virus (SIN.Flu) were generated by using infectious mRNA transcripts, as described elsewhere (12).

Six- to 8-week-old BALB/c mice (Jackson Laboratory, Bar Harbor, Maine) were immunized by various routes, namely, subcutaneously (s.c.), intramuscularly (i.m.), intravenously (i.v.), intraperitoneally (i.p.), and intranasally (i.n.) (17). The magnitudes of the epitope-specific CD8+ T-cell responses were measured 12 days after immunization with an ELISPOT assay. This assay has been described in detail by us (15, 20) and other investigators (4, 5, 11, 16) using various experimental models. In all of these systems it was shown that the results of the ELISPOT correlate closely with the chromium release assay, the ELISPOT being considerably more sensitive and quantitative.

The largest numbers of CS-specific CD8+ T cells, detected 12 days after immunization, were elicited in mice immunized s.c. with 5 × 106 PFU of SIN.Mal (~2 × 103 CS-specific CD8+ T cells/106 spleen cells) (Fig. 1A). The i.m. immunization was only slightly less efficient. Thirty-two days after immunization, the total number of epitope-specific CD8+ T cells had decreased by approximately 50%. As observed at day 12, the magnitude of the CD8+ T-cell response closely depended on the route of immunization, and the greatest response also resulted from s.c. or i.m. inoculation (not shown). It is noteworthy that the magnitude of the anti-SYVPSAEQI CD8+ T-cell response, induced by the RE Sindbis virus, is the greatest we have observed so far, compared to past immunization with other RE vaccinia, influenza, or adenoviruses (17, 19).


View larger version (19K):
[in this window]
[in a new window]
  		FIG. 1.   Results of ELISPOT performed on spleen cells of mice immunized by different routes with RE Sindbis viruses expressing a CS-specific or an NP-specific CD8+ T-cell epitope. (A) Groups of three BALB/c mice were immunized by inoculation with 5 × 106 PFU of SIN.Mal administered s.c., i.m., i.v., i.p., or i.n. (B) Groups of three BALB/c mice were immunized by inoculation with 5 × 106 PFU of SIN.Flu administered by various routes. The numbers of CS- and NP-specific CD8+ T cells in the spleens of the immunized mice were established 12 days after RE virus inoculation by an ELISPOT assay, which detects epitope-specific gamma interferon (IFN-gamma ) secretion by single cells. The corresponding results are expressed as averages ± standard errors of triplicate cultures.

The largest numbers of influenza virus NP-specific CD8+ T cells were also observed upon s.c. or i.m. immunization with SIN.Flu (Fig. 1B). The total numbers of NP-specific CD8+ T cells in the spleens of these mice were smaller than those elicited by inoculation of an equal number of PFU of SIN.Mal, but the rankings of results obtained by the different routes of inoculation were the same.

The number of CS-specific CD8+ T cells closely correlated with the viral dose used for immunization. Animals inoculated s.c. with 107 or 108 PFU of SIN.Mal displayed the largest numbers of CS-specific CD8+ T cells (Fig. 2A). Immunization with doses greater than 109 PFU of SIN.Mal failed to increase the frequency of CS-specific T cells (data not shown). The level of the NP-specific CD8+ T-cell response of s.c. immunized mice was also found to correlate closely with the inoculum size of SIN.Flu. Mice immunized with 108 PFU of the RE virus displayed the highest numbers of NP-specific CD8+ T cells in the spleen, while a larger dose of SIN.Flu, 109 PFU, elicited lower numbers of NP-specific CD8+ T cells (Fig. 2B). This close correlation between virus dose and CD8+ T-cell response may reflect a very low replication rate of the Sindbis virus in vivo. Although pTE3'2J-derived RE double-subgenomic Sindbis viruses are replication competent in vitro, as shown by amplification at a low multiplicity of infection without loss of either infectivity or foreign protein expression, the stability significantly depends on the length and protein product of the foreign gene insert (6, 10, 18). Inoculation with up to 109 PFU of double-subgenomic Sindbis virus recombinants causes inapparent infections in 6- to 8-week-old mice, independent of the route of immunization. Furthermore, productive replication in vivo may be very low, as virus titers in the serum were diminished within the first two days after i.p. inoculation with 5 × 107 PFU and were undetectable thereafter (2a).


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2.   Effect of inoculum size on the numbers of specific splenic CD8+ precursor T cells resulting from immunization. (A) Numbers of gamma interferon (IFN-gamma )-secreting CS-specific CD8+ T cells detected in the spleens of groups of three mice immunized by s.c. inoculation with different doses of SIN.Mal (104 to 108 PFU). (B) Numbers of NP-specific CD8+ T cells in the spleens of groups of five mice immunized by s.c. inoculation with different doses of SIN.Flu (105 to 109 PFU). The numbers of IFN-gamma -secreting CS- and NP-specific CD8+ T cells in the spleens of these mice were detected by an ELISPOT assay 12 days after immunization. The results reflect two identical experiments and are expressed as averages ± standard errors of triplicate cultures.

In order to assess the in vivo antiparasite activity of the specific CD8+ T cells elicited by SIN.Mal, mice were injected s.c. with 108 PFU of this RE virus. For specificity control, other mice were given the same dose of RE virus expressing the influenza NP epitope, SIN.Flu. Two weeks after immunization, both groups of mice, as well as naive animals, were challenged i.v. with 2 × 104 P. yoelii sporozoites. Parasite development was determined 42 h later by measuring plasmodial rRNA levels in the livers of the challenged mice with a competitive reverse transcription-PCR assay, as described elsewhere (3). Mice immunized with SIN.Mal displayed a strong inhibition of parasite development in the liver, resulting in an approximate decrease of 80% of hepatic parasite rRNA levels compared to naive controls (Fig. 3A). The epitope specificity of this protective effect was demonstrated by the fact that mice immunized with SIN.Flu displayed a parasite development similar to that of nonimmunized mice. Furthermore, since SIN.Mal expressed only the 9-mer major histocompatibility complex class I-restricted epitope of the P. yoelii CS protein, the observed inhibition of parasite development could be mediated only by epitope-specific CD8+ T cells.


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 3.   Protective immunity elicited by SIN.Mal and SIN.Flu immunization. (A) Inhibition of liver stage development upon s.c. immunization of five BALB/c mice with 108 PFU of SIN.Mal. As controls for the specificity of protection, five mice were inoculated with SIN.Flu expressing the CD8+ T-cell epitope of the influenza A virus NP, while a third group of five mice was left untreated. Two weeks later, all mice were challenged i.v. with 2 × 104 viable P. yoelii sporozoites and the levels of parasite rRNA present in their livers were determined 42 h after challenge. The results are expressed as averages ± standard deviations of the values obtained from individual mice. (B) Inhibition of viral titers in the lungs of a group of five BALB/c mice immunized by s.c. inoculation with 108 PFU of SIN.Flu. Five additional mice were inoculated s.c. with SIN.Mal, while a third group of mice was left untreated. Two weeks later, all mice were challenged i.n. with 103 PFU of influenza A virus and the viral titers in the lungs were determined on day 4 and, in others, day 7 after challenge. The results are expressed as average virus titers of five mice ± standard deviations. The viral titers of mice immunized with SIN.Flu were significantly lower than those of control groups (P < 0.001 [Student's t test]) both on day 4 and on day 7.

To determine whether immunization with SIN.Flu expressing the influenza NP epitope could elicit protection against influenza virus infection, mice were inoculated s.c. with 108 PFU of SIN.Flu. Other mice were given a comparable dose of SIN.Mal for use as a specificity control. Two weeks after immunization, these and nonimmunized mice were challenged i.n. with 103 PFU of influenza A/WSN/33 virus (subtype H1N1) (13). Viral titers in the lungs of these mice were measured either on day 4 or on day 7 after challenge by using a standard plaque assay to determine the numbers of PFU on Madin-Darby canine kidney cell monolayers (21). Mice immunized with SIN.Flu and challenged with the influenza virus developed much lower virus titers in their lungs than did naive mice or mice immunized with SIN.Mal (Fig. 3B). On day 4, and particularly on day 7, after challenge, the influenza virus titers in the lungs of SIN.Flu-immunized mice were nearly 2 log10 units lower than those of control mice. This supported the view that NP-specific CD8+ T cells, induced by the RE Sindbis virus, were effective in mediating protection against influenza virus infection.

Taken together, these findings reveal that immunization with RE Sindbis virus expressing a single CD8+ epitope of the influenza virus NP or malaria CS protein elicits strong CD8+ T-cell responses and protective immunity against these infections. Previous immunization studies with RE vaccinia viruses expressing the entire malaria CS antigen (13) or the influenza virus NP (1, 9) report the induction of apparently similar or less-efficient protective immunity against these infectious pathogens.

Although Sindbis virus infects humans, this infection is mostly limited to the local skin site, causing a minor rash. Moreover, recent advances in genetic engineering make it feasible to generate replication-defective Sindbis viruses which appear to be nonpathogenic (12). If the immunogenicity of these defective Sindbis viruses remains unaltered, they might be very attractive candidates for the development of safer vaccines against several infectious diseases.

    ACKNOWLEDGMENTS

We thank Chui Ng for excellent technical assistance.

This work was supported by National Institutes of Health grants AI-27458, AI-36526, and AI-33314.

    FOOTNOTES

* Corresponding author. Mailing address: Department of Medical and Molecular Parasitology, New York University School of Medicine, 341 E. 25th St., New York, NY 10010. Phone: (212) 263-6760. Fax: (212) 263-8116. E-mail: fz5{at}is2.nyu.edu.

    REFERENCES
Top
Abstract
Text
References

1. Andrew, M. E., B. E. H. Coupar, D. B. Boyle, and G. L. Ada. 1987. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand. J. Immunol. 25:21-28[Medline].
2. Bender, B. S., C. A. Rowe, S. F. Taylor, L. S. Wyatt, B. Moss, and P. A. Small, Jr. 1996. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:6418-6424[Abstract].
2a. Bergmann, C. Unpublished observations.
3. Briones, M. R. S., M. Tsuji, and V. Nussenzweig. 1996. The large difference in infectivity for mice of Plasmodium berghei and Plasmodium yoelii sporozoites cannot be correlated with their ability to enter into hepatocytes. Mol. Biochem. Parasitol. 77:7-17[Medline].
4. Busch, D. H., and E. G. Pamer. 1998. MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J. Immunol. 160:4441-4448[Abstract/Free Full Text].
5. Butz, E. A., and M. J. Bevan. 1998. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8:167-175[Medline].
6. Chen, J. P., D. Miller, S. Katow, and T. K. Frey. 1995. Expression of the rubella virus structural proteins by an infectious Sindbis virus vector. Arch. Virol. 140:2075-2084[Medline].
7. Davis, N. L., K. W. Brown, and R. E. Johnston. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787[Abstract].
8. Doolan, D. L., M. Sedegah, R. C. Hedstrom, P. Hobart, Y. Charoenvit, and S. L. Hoffman. 1996. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med. 183:1739-1746[Abstract/Free Full Text].
9. Endo, A., S. Itamura, H. Iinuma, S. Funabashi, H. Shida, F. Koide, K. Nerome, and A. Oya. 1991. Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein gene of influenza virus. J. Gen. Virol. 72:699-703[Abstract/Free Full Text].
10. Hahn, C. S., Y. S. Hahn, T. J. Braciale, and C. M. Rice. 1992. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc. Natl. Acad. Sci. USA 89:2679-2683[Abstract/Free Full Text].
11. Lalvani, A., R. Brooks, S. Hambleton, W. J. Britton, A. V. S. Hill, and A. J. McMichael. 1997. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186:859-865[Abstract/Free Full Text].
12. LaStarza, M. W., J. A. Lemm, and C. M. Rice. 1994. Genetic analysis of the nsP3 region of Sindbis virus: evidence for roles in minus-strand and subgenomic RNA synthesis. J. Virol. 68:5781-5791[Abstract/Free Full Text].
13. Li, S., M. Rodrigues, D. Rodriguez, J. R. Rodriguez, M. Esteban, P. Palese, R. S. Nussenzweig, and F. Zavala. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90:5214-5218[Abstract/Free Full Text].
14. London, S. D., A. L. Schmaljon, J. M. Dalrymple, and C. M. Rice. 1992. Infectious enveloped RNA virus antigenic chimeras. Proc. Natl. Acad. Sci. USA 89:207-211[Abstract/Free Full Text].
15. Miyahira, Y., K. Murata, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. M. Rodrigues, and F. Zavala. 1995. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 181:45-54[Medline].
16. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. D. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187[Medline].
17. Murata, K., A. Garcia-Sastre, M. Tsuji, M. Rodrigues, D. Rodriguez, J. R. Rodriguez, R. S. Nussenzweig, P. Palese, M. Esteban, and F. Zavala. 1996. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell. Immunol. 173:96-107[Medline].
18. Pugachev, K. V., P. W. Mason, R. E. Shope, and T. K. Frey. 1995. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212:587-594[Medline].
19. Rodrigues, E. G., F. Zavala, D. Eichinger, J. M. Wilson, and M. Tsuji. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158:1268-1274[Abstract].
20. Rodrigues, M., S. Li, K. Murata, D. Rodriguez, J. R. Rodriguez, I. Bacik, J. R. Bennink, J. W. Yewdell, A. Garcia-Sastre, R. S. Nussenzweig, M. Esteban, P. Palese, and F. Zavala. 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:4636-4648[Abstract].
21. Tite, J. P., C. Hughes-Jenkines, D. O'Callaghan, G. Dougan, S. M. Russel, X.-M. Gao, and F. Y. Liew. 1990. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 71:202-207[Medline].
22. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, L. A. Hawe, K. R. Leander, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery, and M. A. Liu. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749[Abstract/Free Full Text].
23. Xiong, C., R. Levis, P. Shen, S. Schlesinger, C. Rice, and H. V. Huang. 1989. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188-1191[Abstract/Free Full Text].
24. Zhou, X., P. Berglund, H. Zhao, P. Liljeström, and M. Jondal. 1995. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA 92:3009-3013[Abstract/Free Full Text].

J Virol, August 1998, p. 6907-6910, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ophorst, O. J. A. E., Radosevic, K., Havenga, M. J. E., Pau, M. G., Holterman, L., Berkhout, B., Goudsmit, J., Tsuji, M. (2006). Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice. Infect. Immun. 74: 313-320 [Abstract] [Full Text]  
  • Bonaldo, M. C., Garratt, R. C., Marchevsky, R. S., Coutinho, E. S. F., Jabor, A. V., Almeida, L. F. C., Yamamura, A. M. Y., Duarte, A. S., Oliveira, P. J., Lizeu, J. O. P., Camacho, L. A. B., Freire, M. S., Galler, R. (2005). Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J. Virol. 79: 8602-8613 [Abstract] [Full Text]  
  • Tao, D., Barba-Spaeth, G., Rai, U., Nussenzweig, V., Rice, C. M., Nussenzweig, R. S. (2005). Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. JEM 201: 201-209 [Abstract] [Full Text]  
  • Anderson, R. J., Hannan, C. M., Gilbert, S. C., Laidlaw, S. M., Sheu, E. G., Korten, S., Sinden, R., Butcher, G. A., Skinner, M. A., Hill, A. V. S. (2004). Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus. J. Immunol. 172: 3094-3100 [Abstract] [Full Text]  
  • Gorchakov, R., Hardy, R., Rice, C. M., Frolov, I. (2004). Selection of Functional 5' cis-Acting Elements Promoting Efficient Sindbis Virus Genome Replication. J. Virol. 78: 61-75 [Abstract] [Full Text]  
  • Bruna-Romero, O., Schmieg, J., Del Val, M., Buschle, M., Tsuji, M. (2003). The Dendritic Cell-Specific Chemokine, Dendritic Cell-Derived CC Chemokine 1, Enhances Protective Cell-Mediated Immunity to Murine Malaria. J. Immunol. 170: 3195-3203 [Abstract] [Full Text]  
  • Tseng, J.-C., Levin, B., Hirano, T., Yee, H., Pampeno, C., Meruelo, D. (2002). In Vivo Antitumor Activity of Sindbis Viral Vectors. JNCI J Natl Cancer Inst 94: 1790-1802 [Abstract] [Full Text]  
  • Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C. C., Wilson, J. M., Schmieg, J., Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y., Tsuji, M. (2002). Natural Killer T Cell Ligand {alpha}-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines. JEM 195: 617-624 [Abstract] [Full Text]  
  • Brinster, C., Chen, M., Boucreux, D., Paranhos-Baccala, G., Liljestrom, P., Lemmonier, F., Inchauspe, G. (2002). Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83: 369-381 [Abstract] [Full Text]  
  • Bruna-Romero, O., Gonzalez-Aseguinolaza, G., Hafalla, J. C. R., Tsuji, M., Nussenzweig, R. S. (2001). Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA 10.1073/pnas.191380898v1 [Abstract] [Full Text]  
  • Sano, G.-i., Hafalla, J. C.R., Morrot, A., Abe, R., Lafaille, J. J., Zavala, F. (2001). Swift Development of Protective Effector Functions in Naive CD8+ T Cells Against Malaria Liver Stages. JEM 194: 173-180 [Abstract] [Full Text]  
  • Vignuzzi, M., Gerbaud, S., van der Werf, S., Escriou, N. (2001). Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 82: 1737-1747 [Abstract] [Full Text]  
  • Bruna-Romero, O., Gonzalez-Aseguinolaza, G., Hafalla, J. C. R., Tsuji, M., Nussenzweig, R. S. (2001). Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA 98: 11491-11496 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, M.
Right arrow Articles by Zavala, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, M.
Right arrow Articles by Zavala, F.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»